Dihydroartemisinin suppresses the proliferation of Epstein‑Barr virus‑associated gastric carcinoma cells via downregulation of latent membrane protein 2A

Gong,Wei; Zhang,Lei; Yu,Hui; Yu,Qiang; Pan,Wei‑Kang; Wang,Yin; Wu,Xuan‑Lin; Liu,Qiang

doi:10.3892/ol.2018.8950

Dihydroartemisinin suppresses the proliferation of Epstein‑Barr virus‑associated gastric carcinoma cells via downregulation of latent membrane protein 2A

Authors:
- Wei Gong
- Lei Zhang
- Hui Yu
- Qiang Yu
- Wei‑Kang Pan
- Yin Wang
- Xuan‑Lin Wu
- Qiang Liu
View Affiliations

Affiliations: Pediatric Surgery Department, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, Shaanxi 710000, P.R. China, General Surgery Department, Yan'an University Affiliated Hospital, Yan'an, Shaanxi 716000, P.R. China, Department of Imaging, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, Shaanxi 710000, P.R. China
Published online on: June 12, 2018 https://doi.org/10.3892/ol.2018.8950
Pages: 2613-2619

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Treatment of recurrent and metastatic Epstein‑Barr virus‑associated gastric carcinoma (EBVaGC) remains a challenge, particularly in developing countries, due to lack of efficient screening programs. Latent membrane protein 2A (LMP2A) has been reported to serve an important function in the development of EBVaGC. In previous years dihydroartemisinin (DHA), traditionally used as an anti‑malarial agent, has been demonstrated to inhibit tumor growth with low toxicity to normal cells. In the present study, the anti‑tumor effect of DHA in EBVaGC was investigated. The MTT assay was used to compare the viability of untreated and DHA‑treated EBVaGC GT‑38 cells. Flow cytometry was applied to determine the percentage of GT‑38 cells at each stage of the cell cycle. Reverse transcription‑polymerase chain reaction and western blotting were used to determine the expression of the LMP2A gene. The effect of DHA treatment in vivo was evaluated in nude mice bearing GT‑38 tumors. The results of the present study revealed that DHA‑treated cells exhibited a time‑ and dose‑dependent inhibition of viability. DHA significantly increased the apoptotic rate of GT‑38 cells following treatment with 20 µg/ml DHA for 48 h. DHA‑treated GT‑38 cells were blocked in the G0/G1 phase, resulting in an accumulation of G0/G1 phase cells and a significant decrease of G2/M phase cells. In vivo, the results of the present study revealed that DHA significantly inhibited the growth of GT‑38 cell‑transplanted tumors. The mRNA and protein levels of LMP2A were significantly downregulated in the DHA‑treated group compared with the control group. The present data indicated that DHA inhibited cell growth and induced cell apoptosis of the EBVaGC GT‑38 cell line via downregulation of LMP2A. DHA may therefore be a potential therapeutic candidate for the treatment of EBVaGC.

View Figures

View References

1	Kieff E: Epstein-Barr virus and its replicationFundamental Virology. Fields BN, Knipe DM and Howley PM: Lippincott-Raven; Philadelphia, PA: pp. 1109–1162. 1996
2	Epstein MA, Achong BG and Barr YM: Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet. 1:702–703. 1964. View Article : Google Scholar : PubMed/NCBI
3	Gunvén P, Klein G, Henle G, Henle W and Clifford P: Epstein-Barr virus in Burkitt's lymphoma and nasopharyngeal carcinoma. Antibodies to EBV associated membrane and viral capsid antigens in Burkitt lymphoma patients. Nature. 228:1053–1056. 1970. View Article : Google Scholar : PubMed/NCBI
4	Shibata D and Weiss LM: Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol. 140:769–774. 1992.PubMed/NCBI
5	Wu MS, Shun CT, Wu CC, Hsu TY, Lin MT, Chang MC, Wang HP and Lin JT: Epstein-Barr virus-associated gastric carcinomas: Relation to H. pylori infection and genetic alterations. Gastroenterology. 118:1031–1038. 2000. View Article : Google Scholar : PubMed/NCBI
6	Jiang Y, Gao H and Turdu G: Traditional Chinese medicinal herbs as potential AChE inhibitors for anti-Alzheimer's disease: A review. Bioorg Chem. 75:50–61. 2017. View Article : Google Scholar : PubMed/NCBI
7	Shen CY, Jiang JG, Yang L, Wang DW and Zhu W: Anti-ageing active ingredients from herbs and nutraceuticals used in traditional Chinese medicine: pharmacological mechanisms and implications for drug discovery. Br J Pharmacol. 174:1395–1425. 2017. View Article : Google Scholar : PubMed/NCBI
8	Chaturvedi D, Goswami A, Saikia PP, Barua NC and Rao PG: Artemisinin and its derivatives: A novel class of anti-malarial and anti-cancer agents. Chem Soc Rev. 39:435–454. 2010. View Article : Google Scholar : PubMed/NCBI
9	Chen H, Sun B, Pan S, Jiang H and Sun X: Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anticancer Drugs. 20:131–140. 2009. View Article : Google Scholar : PubMed/NCBI
10	Hu CJ, Zhou L and Cai Y: Dihydroartemisinin induces apoptosis of cervical cancer cells via upregulation of RKIP and downregulation of bcl-2. Cancer Biol Ther. 15:279–288. 2014. View Article : Google Scholar : PubMed/NCBI
11	Singh NP and Lai H: Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci. 70:49–56. 2001. View Article : Google Scholar : PubMed/NCBI
12	Luo B, Wang Y, Wang XF, Gao Y, Huang BH and Zhao P: Expression of Epstein-Barr virus genes in EBV-associated gastric carcinomas. World J Gastroenterol. 11:629–633. 2005. View Article : Google Scholar : PubMed/NCBI
13	Hino R, Uozaki H, Murakami N, Ushiku T, Shinozaki A, Ishikawa S, Morikawa T, Nakaya T, Sakatani T, Takada K and Fukayama M: Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res. 69:2766–2774. 2009. View Article : Google Scholar : PubMed/NCBI
14	Zhao J, Liang Q, Cheung KF, Kang W, Lung RW, Tong JH, To KF, Sung JJ and Yu J: Genome-wide identification of Epstein-Barr virus-driven promoter methylation profiles of human genes in gastric cancer cells. Cancer. 119:304–312. 2013. View Article : Google Scholar : PubMed/NCBI
15	Hino R, Uozaki H, Inoue Y, Shintani Y, Ushiku T, Sakatani T, Takada K and Fukayama M: Survival advantage of EBV-associated gastric carcinoma: Survivin up-regulation by viral latent membrane protein 2A. Cancer Res. 68:1427–1435. 2008. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Liu X, Gao Y, Luo B and Zhao Y: Construction and antiapoptosis activities of recombinant adenoviral expression vector carrying EBV latent membrane protein 2A. Gastroenterol Res Pract. 2011:1828322011. View Article : Google Scholar : PubMed/NCBI
18	Crew KD and Neugut AI: Epidemiology of gastric cancer. World J Gastroenterol. 12:354–362. 2006. View Article : Google Scholar : PubMed/NCBI
19	Yau TO, Tang CM and Yu J: Epigenetic dysregulation in Epstein-Barr virus-associated gastric carcinoma: Disease and treatments. World J Gastroenterol. 20:6448–6456. 2014. View Article : Google Scholar : PubMed/NCBI
20	Dhingra V, Rao Vishweshwar K and Narasu Lakshmi M: Current status of artemisinin and its derivatives as antimalarial drugs. Life Sci. 66:279–300. 2000. View Article : Google Scholar : PubMed/NCBI
21	Sun H, Meng X, Han J, Zhang Z, Wang B, Bai X and Zhang X: Anti-cancer activity of DHA on gastric cancer-an in vitro and in vivo study. Tumour Biol. 34:3791–3800. 2013. View Article : Google Scholar : PubMed/NCBI
22	Lee S: Artemisinin, promising lead natural product for various drug developments. Mini Rev Med Chem. 7:411–422. 2007. View Article : Google Scholar : PubMed/NCBI
23	Jiao Y, Ge CM, Meng QH, Cao JP, Tong J and Fan SJ: Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta Pharmacol Sin. 28:1045–1056. 2007. View Article : Google Scholar : PubMed/NCBI
24	Odaka Y, Xu B, Luo Y, Shen T, Shang C, Wu Y, Zhou H and Huang S: Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells. Carcinogenesis. 35:192–200. 2014. View Article : Google Scholar : PubMed/NCBI
25	Longnecker R: Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence? Adv Cancer Res. 79:175–200. 2000. View Article : Google Scholar : PubMed/NCBI
26	zur Hausen A, Brink AA, Craanen ME, Middeldorp JM, Meijer CJ and van den Brule AJ: Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adeno-carcinomas: Expression of the transforming BARF1 gene. Cancer Res. 60:2745–2748. 2000.PubMed/NCBI
27	Miller CL, Lee JH, Kieff E and Longnecker R: An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci USA. 91:772–776. 1994. View Article : Google Scholar : PubMed/NCBI